Keyword: cancer immunotherapy
News
10.01.2023
-
Germany‘s Merck has granted an exclusive license for the tumor-targeting IL-12 fusion protein currently known as M9241 to PDS Biotechnology Corporation, a US-based...
News
30.09.2015
- An alliance of Germany’s Merck KGaA and US pharmaceuticals giant Pfizer has been granted US Food and Drug Administration (FDA) orphan drug status for its investigational cancer...
News
22.09.2015
- Bavarian Nordic, a Danish biotechnology company specializing in research, development and manufacture of active cancer immunotherapies and vaccines for infectious diseases, has...
News
21.09.2015
- US biopharmaceutical group Amgen is to acquire Dezima Pharma, a privately held Dutch biotechnology company focused on developing treatments for dyslipidemia. The transaction is...
News
31.03.2015
- Novartis is accelerating its efforts in the field of cancer immunotherapy with the launch of a dedicated research group and an alliance with US-based Aduro Biotech. The multi-year...
News
19.02.2014
- Swiss pharmaceuticals giant Novartis has announced plans to acquire U.S. biotech firm CoStim. The privately owned cancer therapy specialist based at Cambridge, Massachusetts...
News
04.10.2011
- Merck KGaA said it inked two agreements for collaboration of its Merck Serono division with Ono Pharmaceutical, Osaka, Japan to strengthen its multiple sclerosis and cancer...
